PLUS1
3.55
-0.07 (-1.93%)
-0.07 (-1.93%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BiondVax Pharmaceuticals Ltd | BVXV | NASDAQ | Depository Receipt |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.07 | -1.93% | 3.55 | 18:29:32 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.65 | 3.0981 | 3.74 | 3.63 | 3.62 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 3.55 | 3.68 | 0.13 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,694 | 384,374 | 3.50 | 1,345,299 | 1,182,849 | 2.35 - 62.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:30:39 | formt | 150 | 3.55 | USD |
BiondVax Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 40.92M | 11.53M | 11.53M | - | - | -3.82 | -2.00 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | 0.00% | - | - |
News BiondVax Pharmaceuticals
| Date | Time | Source | Heading |
|---|---|---|---|
| 3/04/2021 | 13:02 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16.. |
| 2/24/2021 | 16:58 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16.. |
| 2/17/2021 | 16:43 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16.. |
| 2/11/2021 | 06:31 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16.. |
| 2/10/2021 | 16:30 | PR Newswire (US) | BiondVax Announces Exercise in Full of Underwriter's.. |
| 2/09/2021 | 06:07 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 2/08/2021 | 14:55 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
BVXV Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic. |
